Jianhua Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jianhua Hu has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Brian S. Henick
Columbia University Irving Medical Center, New York, NY
46 shared publications - Anil K. Rustgi
Columbia University Irving Medical Center 3 Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons New York, New York
42 shared publications - Andres J. Klein-Szanto
Histopathology Facility, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
40 shared publications - Eric W. Lin
Mass General Cancer Center, Harvard Medical School, Charlestown, Massachusetts
40 shared publications - Gizem Efe
Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York 10032, USA
40 shared publications - Hiroshi Nakagawa
Columbia University Irving Medical Center 3 Division of Digestive and Liver Diseases, Department of Medicine, Vagelos College of Physicians and Surgeons New York, New York
40 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (10)
Inverse probability weighting-based mediation analysis for microbiome data
Motivation: Mediation analysis is an important tool for elucidating causal mechanisms in biomedical research and has recently gained increasing attention in microbiome studies. Motivated by a microbiome study of acute myeloid leukemia (AML) patients, we investigate whether the effect of induction chemotherapy (IC) intensity on infection status is mediated through gut microbial taxa. This problem poses substantial methodological challenges due to the high dimensionality, zero inflation, and dependence of microbial mediators, as well as the presence of an exposure-induced mediator–outcome confounder, antibiotic use. Results: To address these challenges, we propose a novel nonparametric identification formula for the interventional indirect effect, a causal mediation estimand that remains identifiable in the presence of exposure-induced mediator–outcome confounding. Building on this identification result, we develop an inverse probability-weighting estimator and construct standard normal bootstrap confidence intervals for inference. Simulation studies demonstrate that the proposed method achieves accurate effect estimation and maintains appropriate type I error rates and power in finite samples. Application to the AML microbiome study provides evidence of a statistically significant interventional indirect effect of IC intensity on infection risk through alterations in the gut microbiome. Availability and implementation: The R code for the simulation studies is available at https://github.com/YX-ZHANG-1/CausalMediationMicrobiome and archived on Zenodo at https://doi.org/10.5281/zenodo.21960802
- 2 October 2026
- Published by Oxford University Press (OUP) in Bioinformatics
- Vol. 42 (10)
Open AccessInverse probability weighting-based mediation analysis for microbiome data
Motivation: Mediation analysis is an important tool for elucidating causal mechanisms in biomedical research and has recently gained increasing attention in microbiome studies. Motivated by a microbiome study of acute myeloid leukemia (AML) patients, we investigate whether the effect of induction chemotherapy (IC) intensity on infection status is mediated through gut microbial taxa. This problem poses substantial methodological challenges due to the high dimensionality, zero inflation, and dependence of microbial mediators, as well as the presence of an exposure-induced mediator–outcome confounder, antibiotic use. Results: To address these challenges, we propose a novel nonparametric identification formula for the interventional indirect effect, a causal mediation estimand that remains identifiable in the presence of exposure-induced mediator–outcome confounding. Building on this identification result, we develop an inverse probability-weighting estimator and construct standard normal bootstrap confidence intervals for inference. Simulation studies demonstrate that the proposed method achieves accurate effect estimation and maintains appropriate type I error rates and power in finite samples. Application to the AML microbiome study provides evidence of a statistically significant interventional indirect effect of IC intensity on infection risk through alterations in the gut microbiome. Availability and implementation: The R code for the simulation studies is available at https://github.com/YX-ZHANG-1/CausalMediationMicrobiome and archived on Zenodo at https://doi.org/10.5281/zenodo.21960802
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Supplementary Figure Legends 1-4
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Supplementary Figure Legends 1-4
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
ERK1/2 signaling pathway in CCL5 knockout cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
ERK1/2 signaling pathway in CCL5 knockout cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Loss of tumor-derived CCL5 reduces tumor cell proliferation in TE-1 cells.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Loss of tumor-derived CCL5 reduces tumor cell proliferation in TE-1 cells.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Targeted CCR5 inhibition replicates CCL5 loss with reduced tumor cell proliferation in vitro and in vivo.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Targeted CCR5 inhibition replicates CCL5 loss with reduced tumor cell proliferation in vitro and in vivo.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Confirmation of CCL5 knockout clones.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Tumor-Derived CCL5 Recruits Cancer-Associated Fibroblasts and Promotes Tumor Cell Proliferation in Esophageal Squamous Cell Carcinoma
Confirmation of CCL5 knockout clones.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Self-Renewing CD8+ T-cell Abundance in Blood Associates with Response to Immunotherapy
Treatment with immune checkpoint blockade (ICB) often fails to elicit durable antitumor immunity. Recent studies suggest that ICB does not restore potency to terminally dysfunctional T cells, but instead drives proliferation and differentiation of self-renewing progenitor T cells into fresh, effector-like T cells. Antitumor immunity catalyzed by ICB is characterized by mobilization of antitumor T cells in systemic circulation and tumor. To address whether abundance of self-renewing T cells in blood is associated with immunotherapy response, we used flow cytometry of peripheral blood from a cohort of patients with metastatic non–small cell lung cancer (NSCLC) treated with ICB. At baseline, expression of T-cell factor 1 (TCF1), a marker of self-renewing T cells, was detected at higher frequency in effector-memory (CCR7–) CD8+ T cells from patients who experienced durable clinical benefit compared to those with primary resistance to ICB. On-treatment blood samples from patients benefiting from ICB also exhibited a greater frequency of TCF1+CCR7–CD8+ T cells and higher proportions of TCF1 expression in treatment-expanded PD-1+CCR7–CD8+ T cells. The observed correlation of TCF1 frequency in CCR7–CD8+ T cells and response to ICB suggests that broader examination of self-renewing T-cell abundance in blood will determine its potential as a noninvasive, predictive biomarker of response and resistance to immunotherapy.
- Open Access
- 6 November 2025
- Published by Springer Nature in BMC Bioinformatics
- Vol. 26 (1) , 1-18
TransST: transfer learning embedded spatial factor modeling of spatial transcriptomics data
Background: Spatial transcriptomics have emerged as a powerful tool in biomedical research because of its ability to capture both the spatial contexts and abundance of the complete RNA transcript profile in organs of interest. However, limitations of the technology such as the relatively low resolution and comparatively insufficient sequencing depth make it difficult to reliably extract real biological signals from these data. To alleviate this challenge, we propose a novel transfer learning framework, referred to as TransST, to adaptively leverage the cell-labeled information from external sources in inferring cell-level heterogeneity of a target spatial transcriptomics data. Results: Applications in several real studies as well as a number of simulation settings show that our approach significantly improves existing techniques. For example, in the breast cancer study, TransST successfully identifies five biologically meaningful cell clusters, including the two subgroups of cancer in situ and invasive cancer; in addition, only TransST is able to separate the adipose tissues from the connective issues among all the studied methods. Conclusions: In summary, the proposed method TransST is both effective and robust in identifying cell subclusters and detecting corresponding driving biomarkers in spatial transcriptomics data.
- 6 November 2025
- Published by Springer Nature in BMC Bioinformatics
- Vol. 26 (1) , 1-18
Open AccessTransST: transfer learning embedded spatial factor modeling of spatial transcriptomics data
Background: Spatial transcriptomics have emerged as a powerful tool in biomedical research because of its ability to capture both the spatial contexts and abundance of the complete RNA transcript profile in organs of interest. However, limitations of the technology such as the relatively low resolution and comparatively insufficient sequencing depth make it difficult to reliably extract real biological signals from these data. To alleviate this challenge, we propose a novel transfer learning framework, referred to as TransST, to adaptively leverage the cell-labeled information from external sources in inferring cell-level heterogeneity of a target spatial transcriptomics data. Results: Applications in several real studies as well as a number of simulation settings show that our approach significantly improves existing techniques. For example, in the breast cancer study, TransST successfully identifies five biologically meaningful cell clusters, including the two subgroups of cancer in situ and invasive cancer; in addition, only TransST is able to separate the adipose tissues from the connective issues among all the studied methods. Conclusions: In summary, the proposed method TransST is both effective and robust in identifying cell subclusters and detecting corresponding driving biomarkers in spatial transcriptomics data.
- 1 June 2025
- Published by Institute of Mathematical Statistics in The Annals of Applied Statistics
- Vol. 19 (2) , 943-966
Biomarker detection for disease classification in longitudinal microbiome data
The microbiome has been found to have a close relationship with human health. Advancements in sequencing technologies have enabled in-depth studies of microbial communities and their associations with various diseases. When analyzing microbiome data, it is common to perform compositional scale normalization to ensure statistical validity. This requires special treatment to address the unique characteristics of microbiome data. Furthermore, biomedical studies often involve repeated measurements of microbial samples, which adds complexity to the data analysis. In this paper we focus on a liver transplant microbiome study. The main objective is to investigate the association between the colonization status of multidrug-resistant bacteria (MDRB) and the longitudinal microbial abundance profile. To accomplish this, we employ a regularized functional logistic regression model in our analysis. Specifically, we utilize the log-contrast model with a low-rank approximation to handle the compositional covariates and nonconvex penalties to select the important components in the covariate space. We propose an efficient estimation algorithm and establish the oracle property of the estimator. We name this new development as Functional Compositional data Quadratic Method (FCQM). We demonstrate the promise of the proposed method with extensive simulation studies and the liver transplant application.
- 1 June 2025
- Published by Institute of Mathematical Statistics in The Annals of Applied Statistics
- Vol. 19 (2) , 943-966
Biomarker detection for disease classification in longitudinal microbiome data
The microbiome has been found to have a close relationship with human health. Advancements in sequencing technologies have enabled in-depth studies of microbial communities and their associations with various diseases. When analyzing microbiome data, it is common to perform compositional scale normalization to ensure statistical validity. This requires special treatment to address the unique characteristics of microbiome data. Furthermore, biomedical studies often involve repeated measurements of microbial samples, which adds complexity to the data analysis. In this paper we focus on a liver transplant microbiome study. The main objective is to investigate the association between the colonization status of multidrug-resistant bacteria (MDRB) and the longitudinal microbial abundance profile. To accomplish this, we employ a regularized functional logistic regression model in our analysis. Specifically, we utilize the log-contrast model with a low-rank approximation to handle the compositional covariates and nonconvex penalties to select the important components in the covariate space. We propose an efficient estimation algorithm and establish the oracle property of the estimator. We name this new development as Functional Compositional data Quadratic Method (FCQM). We demonstrate the promise of the proposed method with extensive simulation studies and the liver transplant application.